0000000000905316

AUTHOR

Jesús Escribá-alepuz

showing 3 related works from this author

Muscle Function Differences between Patients with Bulbar and Spinal Onset Amyotrophic Lateral Sclerosis. Does It Depend on Peripheral Glucose?

2021

Background: One of the pathogenic mechanisms of ALS disease is perturbed energy metabolism particularly glucose metabolism. Given the substantial difference in the severity and the prognosis of the disease, depending on whether it has a bulbar or spinal onset, the aim of the study was to determine metabolic differences between both types of ALS, as well as the possible relationship with muscle function. Materials and Methods: A descriptive, analytical, quantitative, and transversal study was carried out in hospitals and Primary Care centers in the region of Valencia, Spain. Fasting glucose and alkaline phosphatase (AP) levels in venous blood, muscle percentage, fat percentage, muscle streng…

amyotrophic lateral sclerosis:Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose [Medical Subject Headings]lcsh:Medicine:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Feeding Behavior::Fasting [Medical Subject Headings]DiseaseGastroenterology:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicineAmyotrophic lateral sclerosisglucosespinal onset ALS:Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Esterases::Phosphoric Monoester Hydrolases::Alkaline Phosphatase [Medical Subject Headings]:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Hospitals [Medical Subject Headings]0303 health sciences:Anatomy::Musculoskeletal System::Muscles [Medical Subject Headings]General MedicineVenous bloodFuerza muscular:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]PeripheralAlkaline phosphataseFosfatasa alcalinaalkaline phosphatasemedicine.medical_specialtyBarthel indexbulbar onset ALS:Diseases::Nervous System Diseases::Neurodegenerative Diseases::Motor Neuron Disease::Amyotrophic Lateral Sclerosis [Medical Subject Headings]Carbohydrate metabolismResistencia a la insulinaArticle03 medical and health sciences:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance [Medical Subject Headings]Insulin resistance:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Muscle Strength [Medical Subject Headings]Internal medicinemedicine030304 developmental biology:Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings]Muscle strengthbusiness.industrylcsh:RInsulin resistance:Phenomena and Processes::Metabolic Phenomena::Metabolism::Energy Metabolism [Medical Subject Headings]medicine.diseaseAtrofia muscular espinalGlucosa:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]businessEsclerosis amiotrófica lateral030217 neurology & neurosurgery
researchProduct

Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Incr…

2021

Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood. After 4 months of intervention with 27 MS patients, we observed that Hp does not significantly increase, alongside a significant decrease in IL-6 and a significant increase in muscle percentage. At the same time, Hp synthesis is considerably and positively correlated with IL-6 both before and after treatment

0301 basic medicineAdultMalemedicine.medical_specialtyepigallocatechin gallateMultiple Sclerosisbeta-hydroxybutyratemuscleinterleukin 6Pilot ProjectsEpigallocatechin gallateMicrobiologyBiochemistryCatechinArticlePathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBeta hydroxybutyrateInternal medicinemedicineHumansIn patientInterleukin 6Muscle SkeletalMolecular Biologybiology3-Hydroxybutyric AcidHaptoglobinsbusiness.industryInterleukin-6Multiple sclerosisHaptoglobinfood and beveragesMiddle Agedmedicine.diseaseQR1-502haptoglobin030104 developmental biologyEndocrinologychemistrybiology.proteinKetone bodiesFemalebusiness030217 neurology & neurosurgeryBiomarkersBiomolecules
researchProduct

Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report.

2021

Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk…

Malemedicine.medical_specialtyepigallocatechin gallateCase ReportWalk TestDiseaseEpigallocatechin gallatePlaceboCatechinchemistry.chemical_compoundTooth diseaseCharcot-Marie-Tooth DiseaseInternal medicineMedicineHumansCharcot-Marie-Tooth disease type 2lcsh:R5-920IL-6biologyHand Strengthbusiness.industrymotor activityAryldialkylphosphataseParaoxonaseparaoxonase 1General MedicineAnthropometryPON1chemistryWalk testbiology.proteinFemalebusinesslcsh:Medicine (General)
researchProduct